China Biologic Products rose by two to three points, with the progress of its innovative drug pipeline providing a floor; Innovent Biologics, Intellia Therapeutics, and 3SBio have basically been flat. The large-cap stocks are stable, with no surprises nor bombs, which is the recent norm for the Hong Kong and U.S. biopharmaceutical leading group.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
